Loading provider…
Loading provider…
Neurology Physician in Los Angeles, CA
NPI: 1265451173Primary Employer
USC Care Medical Group, Inc
keckmedicine.org
HQ Phone
Get MD John's Phone Numberphone_androidMobile
Get MD John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1997 - 2027

American Board of Psychiatry and Neurology
Neurology
McGill University Faculty of Medicine
Medical School
Until 1993
Baylor College Of Medicine
bcm.edu
Internship • Internal Medicine
1993 - 1994
Residency • Neurology
1994 - 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 73 | 176 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 70 | 70 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 70 | 81 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 48 | 54 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 39 | 43 |
Children of persons with Alzheimer disease: what does the future hold?
Authors: Izabella Gokhman, Deborah Blacker, Nelson Freimer, Claudia Kawas
Journal: Alzheimer Dis Assoc Disord
Probing Estrogen Sulfotransferase-Mediated Inflammation with [11C]-PiB in the Living Human Brain.
Authors: Andrew Surmak, David Liebeskind, Alexander Aabedi
Journal: J Alzheimers Dis
Update on Alzheimer's and the Dementias: Introduction.
Authors: John Ringman
Publication Date: 2017-04-16
Lead Sponsor: Eli Lilly and Company
Collaborators: Alzheimer's Therapeutic Research Institute
Intervention / Treatment: DRUG: Placebo, DRUG: Solanezumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Solanezumab
Lead Sponsor: University of California, Los Angeles
Collaborators: John Douglas French Foundation
Intervention / Treatment: DIETARY_SUPPLEMENT: Placebo, DIETARY_SUPPLEMENT: caprylidene